Connect Biopharma

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. Our lead product candidate, CBP-201 — an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) — has been in clinical trials for the treatment of AD, asthma, and CRSwNP. Our second lead product candidate, CBP-307 — a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1) — has been in clinical trials for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we have started the clinical development of an additional product candidate, CBP-174 — a peripherally acting antagonist of histamine receptor 3 — for the treatment of pruritus associated with AD. With clinical development activities in the United States, China, Europe, and Australia, and operations in those geographies as well as Hong Kong, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com

Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with rare diseases.

AnaptysBio

AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.

therapeutics inc.

Therapeutics Inc. is a drug research and development company focusing on integration of clinical and regulatory strategies, trial design, product development, and marketplace analysis. The company’s services include clinical development project management, medical monitoring, and non-clinical development such as designing and managing pharmacology and toxicology programs. Therapeutics develops drugs and devices for acne, psoriasis, melasma, excess facial hair, injectable fillers, photoaging, and onychomycosis. The company was founded in 1997 and is headquartered in San Diego, California.

Artiva Biotherapeutics

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.